ReviewReproduction & fertility2026
Macrophage efferocytosis in pregnancy and pregnancy complications.
Review in Reproduction & fertility, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
abstractEfferocytosis is a vital process during early placental development that removes apoptotic cells generated through decidualisation and controls inflammation. As pregnancy progresses and levels of apoptotic placental cells increase, macrophage efferocytosis remains essential to maintain a healthy pregnancy. There is mounting evidence that dysfunctional macrophage efferocytosis is implicated in the pathogenesis of multiple pregnancy complications. This includes disorders of malplacentation, such as preeclampsia and fetal growth restriction, wherein impaired spiral artery remodelling and inflammation in the decidua impair placental vascularisation leading to maternal hypertension, or impaired fetal growth. As a shift in macrophage phenotype and cytokine secretion is required for the onset of labour, alterations in phenotype earlier in pregnancy may be associated with preterm birth. In rarer pregnancy complications, such as chronic histiocytic intervillositis, impaired efferocytosis and wound healing by infiltrating intervillous, macrophages may contribute to their excessive recruitment into the intervillous space, hindering placental function. In this review, we describe the importance of efferocytosis by various maternal macrophage populations in the placenta and review the evidence of how impaired efferocytosis contributes to pathology. Furthermore, therapeutic targeting of macrophage efferocytosis and how this may be used to prevent or treat obstetric conditions are explored. LAY SUMMARY: During pregnancy, the body must safely clear away any dead cells in the womb to allow the placenta to grow and develop properly. This clean-up process is called efferocytosis, and it is carried out by immune cells known as macrophages. By removing these dying cells, macrophages help prevent inflammation and create the right environment for a healthy pregnancy. When efferocytosis does not work as it should, it can contribute to pregnancy complications. For example, if dead cells are not removed, the mother may develop high blood pressure, or the baby may not grow as expected. In rare pregnancy conditions, too many macrophages build up in the placenta. This build-up can interfere with the placenta's ability to support the baby and can lead to stillbirth. In this review, we discuss why macrophage efferocytosis is so important for normal placental development and explore how problems in this process may lead to disease. We also consider new treatment ideas that could help control how macrophages work to prevent or manage pregnancy complications.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.